BREAKING NEWS: CRISPR gene-editing therapy tested in a person for the first time

This message contains graphics. If you do not see the graphics, click here to view.

BREAKING NEWS CRISPR gene-editing therapy tested in a person for the first time Steve Gschmeissner/Science Photo Library A Chinese group has become the first to deliver cells whose genes were edited using the revolutionary CRISPR/Cas9 technique into a person. On 28 October, a team led by Lu You, an oncologist at Sichuan University in Chengdu, delivered the modified cells into a patient with an aggressive form of lung cancer — metastatic non-small cell lung cancer— as part of a clinical trial at the West China Hospital, which is affiliated with Sichuan University. Access the news article online. Register for updates from Nature Subscribe to Nature for £60, €65 or $70!     Share:   Google+    Facebook    LinkedIn    Reddit     StumbleUpon    Twitter    Digg         As a registered user of Nature Publishing Group's Web sites, our database indicates that you have opted-in to receive product information and special offers. If you no longer wish to receive these e-mails or to discontinue all e-mail services from Nature Publishing Group please update your online account. Modify My Account (Log in to be recognised as a Nature.com registrant). For further information on technical assistance | print subscriptions | other enquiries. Nature Publishing Group | Principal offices: London | New York and Tokyo, and offices in cities worldwide including Basingstoke | Barcelona | Boston | Buenos Aires | Cairo | Delhi | Heidelberg | Madrid | Melbourne | Mexico City | Mumbai | Munich | Paris | San Francisco | Sao Paulo | Seoul | Shanghai and Washington DC. Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | US © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All rights reserved.